Manikandan M.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manikandan M. has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Malay Patra
Tata Institute of Fundamental Research Homi Bhabha Road
6 shared publications Chinmoy Patra
Department of Developmental Biology, Agharkar Research Institute, G G Agarkar Road, Pune, Maharashtra 411004, India
2 shared publicationsDivyesh S. Shelar
Department of Chemistry, University of Mumbai, Mumbai, 400098, India
2 shared publicationsGauri S. Malankar
Department of Chemistry, University of Mumbai, Mumbai, 400098, India
2 shared publications- Raymond John Butcher
Department of Chemistry, Howard University, 525 College Street NW, Washington DC 20059, USA
2 shared publications - Sudesh T. Manjare
Department of Chemistry University of Mumbai Mumbai India
2 shared publications
Latest Publications
- 19 August 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (9) , 1482-1490
Analysis of Antiangiogenic Potential and Cell Death Mechanism of a Kinetically Inert Platinum Antitumor Agent
Cancer is a multifaceted disease involving various pathological processes, including uncontrolled proliferation, development of resistance, angiogenesis, metastasis, etc. Therefore, chemotherapeutic agents capable of simultaneously inhibiting proliferation, circumventing chemoresistance, and inhibiting angiogenesis can address multiple aspects of cancer progression. We recently identified a highly promising kinetically inert platinum antitumor agent, namely, Pt-1, that can circumvent cisplatin resistance and showed negligible nephrotoxicity. In this study, we explored the antiangiogenic potential and elucidated the detailed mechanism of cell death through which it exerts its antitumor activity. Pt-1 strongly inhibited angiogenesis in a zebrafish in vivo model at its therapeutically relevant nontoxic dose. Further, Pt-1 exerted antitumor activity through necroptosis- and paraptosis-mediated cell death. Taken together, the combination of antitumor activity with antiangiogenic property in Pt-1 makes it a highly promising antitumor candidate.
- 19 August 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (9) , 1482-1490
Analysis of Antiangiogenic Potential and Cell Death Mechanism of a Kinetically Inert Platinum Antitumor Agent
Cancer is a multifaceted disease involving various pathological processes, including uncontrolled proliferation, development of resistance, angiogenesis, metastasis, etc. Therefore, chemotherapeutic agents capable of simultaneously inhibiting proliferation, circumventing chemoresistance, and inhibiting angiogenesis can address multiple aspects of cancer progression. We recently identified a highly promising kinetically inert platinum antitumor agent, namely, Pt-1, that can circumvent cisplatin resistance and showed negligible nephrotoxicity. In this study, we explored the antiangiogenic potential and elucidated the detailed mechanism of cell death through which it exerts its antitumor activity. Pt-1 strongly inhibited angiogenesis in a zebrafish in vivo model at its therapeutically relevant nontoxic dose. Further, Pt-1 exerted antitumor activity through necroptosis- and paraptosis-mediated cell death. Taken together, the combination of antitumor activity with antiangiogenic property in Pt-1 makes it a highly promising antitumor candidate.
- 3 October 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (19) , 13481-13500
Development of a Highly In Vivo Efficacious Dual Antitumor and Antiangiogenic Organoiridium Complex as a Potential Anti-Lung Cancer Agent
While the phenomenal clinical success of blockbuster platinum (Pt) drugs is highly encouraging, the inherent and acquired resistance and dose-limiting side effects severely limit their clinical application. To find a better alternative with translational potential, we synthesized a library of six organo-IrIII half-sandwich [(η5-CpX)Ir(N∧N)Cl]+-type complexes. In vitro screening identified two lead candidates [(η5-CpXPh)Ir(Ph2Phen)Cl]+ (5, CpXPh = tetramethyl-phenyl-cyclopentadienyl and Ph2Phen = 4,7-diphenyl-1,10-phenanthroline) and [(η5-CpXBiPh)Ir(Ph2Phen)Cl]+ (6, CpXBiPh = tetramethyl-biphenyl-cyclopentadienyl) with nanomolar IC50 values. Both 5 and 6 efficiently overcame Pt resistance and presented excellent cancer cell selectivity in vitro. Potent antiangiogenic properties of 6 were demonstrated in the zebrafish model. Satisfyingly, 6 and its nanoliposome Lipo-6 presented considerably higher in vivo antitumor efficacy as compared to cisplatin, as well as earlier reported IrIII half-sandwich complexes in mice bearing the A549 non-small lung cancer xenograft. In particular, complex 6 is the first example of this class that exerted dual in vivo antiangiogenic and antitumor properties.
- 3 October 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (19) , 13481-13500
Development of a Highly In Vivo Efficacious Dual Antitumor and Antiangiogenic Organoiridium Complex as a Potential Anti-Lung Cancer Agent
While the phenomenal clinical success of blockbuster platinum (Pt) drugs is highly encouraging, the inherent and acquired resistance and dose-limiting side effects severely limit their clinical application. To find a better alternative with translational potential, we synthesized a library of six organo-IrIII half-sandwich [(η5-CpX)Ir(N∧N)Cl]+-type complexes. In vitro screening identified two lead candidates [(η5-CpXPh)Ir(Ph2Phen)Cl]+ (5, CpXPh = tetramethyl-phenyl-cyclopentadienyl and Ph2Phen = 4,7-diphenyl-1,10-phenanthroline) and [(η5-CpXBiPh)Ir(Ph2Phen)Cl]+ (6, CpXBiPh = tetramethyl-biphenyl-cyclopentadienyl) with nanomolar IC50 values. Both 5 and 6 efficiently overcame Pt resistance and presented excellent cancer cell selectivity in vitro. Potent antiangiogenic properties of 6 were demonstrated in the zebrafish model. Satisfyingly, 6 and its nanoliposome Lipo-6 presented considerably higher in vivo antitumor efficacy as compared to cisplatin, as well as earlier reported IrIII half-sandwich complexes in mice bearing the A549 non-small lung cancer xenograft. In particular, complex 6 is the first example of this class that exerted dual in vivo antiangiogenic and antitumor properties.
- 19 September 2023
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 10 (22) , 6711-6727
A hydrolytically stable oxo-rhenium( v ) antitumor agent for synergistic combination therapy with cisplatin: from synthesis and mechanistic studies to toxicity assessment in zebrafish
A hydrolytically stable oxo-Re( v ) complex presents potent in vitro antitumor activity as a single agent or in combination with cisplatin and negligible toxicity in zebrafish.
- 19 September 2023
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 10 (22) , 6711-6727
A hydrolytically stable oxo-rhenium( v ) antitumor agent for synergistic combination therapy with cisplatin: from synthesis and mechanistic studies to toxicity assessment in zebrafish
A hydrolytically stable oxo-Re( v ) complex presents potent in vitro antitumor activity as a single agent or in combination with cisplatin and negligible toxicity in zebrafish.
- 20 August 2022
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 46 (36) , 17610-17618
Selective detection of hypochlorous acid in living cervical cancer cells with an organoselenium-based BOPPY probe
The synthesis and crystal structure of the first selenium-containing BOPPY probe. The probe is selective for exogenous and endogenous HOCl detection in HeLa cells with a “turn-on” fluorescence response.
- 20 August 2022
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 46 (36) , 17610-17618
Selective detection of hypochlorous acid in living cervical cancer cells with an organoselenium-based BOPPY probe
The synthesis and crystal structure of the first selenium-containing BOPPY probe. The probe is selective for exogenous and endogenous HOCl detection in HeLa cells with a “turn-on” fluorescence response.
- 30 June 2022
- Published by Wiley in Chemistry – A European Journal
- Vol. 28 (46) , e202201259
A Rationally Designed Bimetallic Platinum (II)‐Ferrocene Antitumor Agent Induces Non‐Apoptotic Cell Death and Exertsin VivoEfficacy
Despite phenomenal clinical success, the efficacy of platinum anticancer drugs is often compromised due to inherent and acquired drug resistant phenotypes in cancers. To circumvent this issue, we designed two heterobimetallic platinum (II)‐ferrocene hybrids that display multi‐pronged anticancer action. In cancer cells, our best compound,2, platinates DNA, produces reactive oxygen species, and has nucleus, mitochondria, and endoplasmic reticulum as potential targets. The multi‐modal mechanism of action of these hybrid agents lead to non‐apoptotic cell death induction which enables circumventing apoptosis resistance and significant improvement in platinum cross resistance profile. Finally, in addition to describing detail mechanistic insights, we also assessed its stability in plasma and demonstrate anticancer efficacy in an in vivo A2780 xenograft model. Strikingly, compared to oxaliplatin, our compound displays better tolerability, safety profile and efficacy in vivo.
- 30 June 2022
- Published by Wiley in Chemistry – A European Journal
- Vol. 28 (46) , e202201259
A Rationally Designed Bimetallic Platinum (II)‐Ferrocene Antitumor Agent Induces Non‐Apoptotic Cell Death and Exertsin VivoEfficacy
Despite phenomenal clinical success, the efficacy of platinum anticancer drugs is often compromised due to inherent and acquired drug resistant phenotypes in cancers. To circumvent this issue, we designed two heterobimetallic platinum (II)‐ferrocene hybrids that display multi‐pronged anticancer action. In cancer cells, our best compound,2, platinates DNA, produces reactive oxygen species, and has nucleus, mitochondria, and endoplasmic reticulum as potential targets. The multi‐modal mechanism of action of these hybrid agents lead to non‐apoptotic cell death induction which enables circumventing apoptosis resistance and significant improvement in platinum cross resistance profile. Finally, in addition to describing detail mechanistic insights, we also assessed its stability in plasma and demonstrate anticancer efficacy in an in vivo A2780 xenograft model. Strikingly, compared to oxaliplatin, our compound displays better tolerability, safety profile and efficacy in vivo.
- 10 June 2022
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 51 (26) , 10069-10076
A BOPHY based fluorescent probe for Hg2+via NTe2 chelation
The first tellurium derivative of BOPHY is reported. The probe could detect Hg2+ inside HeLa cells with an instantaneous fluorescence turn-on response in the nanomolar range.
- 10 June 2022
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 51 (26) , 10069-10076
A BOPHY based fluorescent probe for Hg2+via NTe2 chelation
The first tellurium derivative of BOPHY is reported. The probe could detect Hg2+ inside HeLa cells with an instantaneous fluorescence turn-on response in the nanomolar range.